

1 Parametric assessment of the effect of cochlear implant positioning 2 on brain MRI artefacts at 3 Tesla

3
4 Short running head: MRI and CI location

5
6 RS Dewey 1,2,3, RA Dineen 1,3,4, M Clemence 5, O Dick 6, R Bowtell 1, PT Kitterick 2,3

7
8 1. Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham,
9 NG7 2RD, UK.

10 2. Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham,
11 NG7 2UH, UK.

12 3. National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre,
13 Nottingham, NG1 5DU, UK.

14 4. Radiological Sciences, Division of Clinical Neuroscience, School of Medicine, University of
15 Nottingham, NG7 2UH, UK.

16 5. Philips Healthcare, Best, Netherlands.

17 6. Radiology Department, Nottingham University Hospitals NHS Trust, Queens Medical Centre,
18 Nottingham, NG7 2UH.

19
20 **Address correspondence to:** Rebecca Dewey; National Institute for Health Research (NIHR)
21 Nottingham Biomedical Research Centre, Nottingham, UK. NG1 5DU; +441158232638;
22 Rebecca.dewey@physics.org

23
24 **Sources of support:** This research was funded by the Nottingham Hospitals Charity grant and the
25 infrastructure funding from the National Institute for Health Research. PTK's institution has received
26 research grants from a manufacturer of cochlear implants, Cochlear Europe Ltd. The authors declare
27 no other conflict of interest.

28 29 **Acknowledgements**

30 The authors would like to acknowledge Priya Archar at ENT Nottingham, Nottingham University
31 Hospitals NHS Trust, Queen's Medical Centre, Nottingham, for her contribution of drawing the
32 plausible implant locations on the silicone swimming cap while worn by one of the participants.
33

1 Parametric assessment of the effect of cochlear implant positioning 2 on brain MRI artefacts at 3 Tesla

3

4 Abstract

5 **Background:** Brain magnetic resonance imaging (MRI) in patients with cochlear implants (CIs) is
6 impacted by image artefacts.

7 **Hypothesis:** The optimal positioning of the CI to minimise artefacts is unknown. This study aimed to
8 characterise the dependence of the extent and distribution of the artefact on CI positioning.

9 **Methods:** Three normally-hearing individuals underwent MRI using a standard T1-weighted [3D](#)
10 sequence. Scans were acquired with a non-functioning CI placed underneath a swimming cap at four
11 plausible scalp positions on each side, and without the CI in situ. The artefact in each image was
12 assessed quantitatively using voxel-based techniques. Two radiologists also independently rated the
13 likely impact of the artefact on detection of pathology for 20 neuroradiological locations.

14 **Results:** The procedure was well tolerated. The most postero-inferior CI positions resulted in the
15 smallest apparent artefacts. Radiological evaluations suggested that artefacts would likely limit
16 pathology detection in the ipsilateral temporal, parietal and occipital lobes, regardless of CI location.
17 Pathology detection in contralateral structures and anterior corpus callosum was rarely affected.
18 Certain CI locations appeared to selectively spare ipsilateral structures, e.g., postero-inferior CI
19 locations selectively spared ipsilateral midbrain, deep grey matter, and frontal lobes.

20 **Conclusion:** A CI placed under a swimming cap is a feasible tool for observing the effect of CI
21 location on image usability within a single subject and potentially informing surgical planning.
22 Regardless of CI placement, artefacts involving ipsilateral parietal, temporal and occipital lobes
23 severely limited diagnostic image utility. Between 35% and 70% of neuroradiological features were
24 deemed unaffected by the implant.

25

26

27 **Hypothesis**

28 The optimal positioning of the CI to minimise such artefacts is unknown. This study aimed to
29 characterise the dependence of the extent and distribution of the CI artefact on CI positioning.

30

31 **Introduction**

32 Magnetic resonance imaging (MRI) forms a non-invasive imaging modality that is sensitive to many
33 pathologies, and as such is often the preferred imaging technique for diagnosis and on-going disease
34 evaluation. MRI is widely used in imaging diseases of the brain because the excellent soft tissue
35 contrast and availability of a range of sequences that are sensitive to different pathological
36 processes provide great diagnostic value. A cochlear implant (CI) is a device that provides auditory
37 input for deaf individuals and comprises an implanted component (receiver-stimulator) and an
38 external component (speech/sound processor) worn behind the ear. The implanted component
39 contains a retaining magnet and a hermetically-sealed package with electronics placed under the
40 scalp, and its presence raises MRI safety concerns [1], such as displacement of the internal retaining
41 magnet and unintended acoustic stimulation [2].

42

43 Major manufacturers have revised the design of the implanted magnet to include a rotating
44 component that minimises torque on the CI when it is placed in a magnetic field, thus improving
45 patient comfort during MRI. However, clinical imaging of the head of CI-implanted patients is still
46 confounded by substantial image artefacts caused by both the retaining magnet and the electronic
47 components [3,4]. As a result, MRI is often avoided in this population. Computed tomography (CT)
48 provides an alternative imaging technique that avoids the MRI-related safety concerns, but
49 sensitivity to certain pathologies may not be as good as MRI, and image artefacts due to beam
50 attenuation by the metallic components can also degrade CT images. Metal artefact reduction
51 sequences (MARS) have recently been applied to spin-echo sequences on many scanner systems,
52 but are associated with increased radiofrequency energy and consequently increased scan durations
53 that could limit their utility in certain clinical settings [5].

54

55 Certain medical conditions associated with hearing loss may require regular (e.g. annual) MRI
56 assessment to monitor disease progression. For example, neurofibromatosis type 2 (NF2), is a
57 complex genetic condition that causes benign tumours (schwannomas) to grow along the nerves.
58 Most commonly this affects the vestibular nerves, and while benign, vestibular schwannomas cause
59 hearing loss for which cochlear implantation may be considered as a treatment when the cochlear
60 nerve is anatomically preserved [6,7,8,9]. As annual monitoring of the brain is advised for people

61 with NF2 [10], the ability to safely acquire diagnostic-quality MRI in those with cochlear implants is
62 important. A similar argument can be made for children with congenital disorders such as
63 congenital cytomegalovirus infection or neurogenetic / mitochondrial disorders associated with
64 deafness that may benefit from cochlear implantation [11,12,13], for which on-going MRI studies
65 may be important for monitoring the associated brain disease. Furthermore, as cochlear
66 implantation becomes widespread, MRI will become more important for diagnosing and monitoring
67 unrelated, acquired brain pathologies in CI-implanted patients.

68

69 Removal of the retaining magnet is an effective method of reducing image artefacts due to CIs
70 [14,15]. However, this approach requires the patient to undergo additional surgical procedures
71 before and after each scan and may impose a period of auditory deprivation while wounds heal.
72 Non-invasive methods of minimising the CI artefact would therefore significantly minimise patient
73 burden in cases where regular brain MRI is indicated and address potential barriers preventing this
74 patient group from benefitting from MRI imaging. Both the position of the CI implantation site [16]
75 and the orientation of the head in the MR scanner [17] affect which regions of the image are
76 affected by artefact and which anatomical features are visible. This study aimed to develop an
77 approach to allow the evaluation of CI artefacts as the position of the implantable component is
78 varied parametrically across different scalp positions. We demonstrate the utility of using a non-
79 functioning CI device placed at 8 plausible surgical positions on the scalp of healthy volunteers by
80 evaluating the extent and distribution of the CI artefact, and its impact on the diagnostic quality of a
81 T1-weighted structural brain MRI sequence.

82

83 **Materials and Methods**

84 **Participants**

85 No formal sample size calculations were performed owing to the exploratory nature of the study
86 activities. Experimental procedures conformed to the World Medical Association's Declaration of
87 Helsinki and were approved by the University Faculty of Medicine and Health Sciences Research
88 Ethics Committee (reference: 460-2001). All participants gave written informed consent. Participants
89 were 23, 30 and 34 years old. Two of the participants were female.

90

91 **Image acquisition**

92 MRI data were acquired on a Philips 3.0 T Achieva MR scanner (Philips Healthcare, Best,
93 Netherlands) using a 32-channel SENSE head coil. The scanner provided the MR conditional
94 requirements for the Cochlear CI 612 implant by imposing the indicated safe performance limits

95 (ScanWise Implant, Philips Healthcare). Data were collected using a standard 3D-T1-weighted
96 acquisition, taken from the manufacturer's defaults, so that it would be analogous to what would be
97 used in the clinical setting, and would ensure that the extent of the artefact was not
98 underestimated. The sequence used a steady-state (fast-field echo; FFE) gradient echo (GE)
99 acquisition at 1.5 mm isotropic spatial resolution, reconstructed to 1 mm isotropic; field of view of
100 240×240×160 mm³, echo time (TE) of 1.52 ms; repetition time (TR) of 25 ms, flip angle = 30°;
101 bandwidth = 285 Hz, and sensitivity encoding (SENSE) factor 1.6. A stack comprising 150 contiguous
102 sagittal slices provided whole-head coverage. The acquisition had a SAR of 0.484 Wkg⁻¹, took 2 min
103 57 s and was repeated nine times on each participant (8 scans with implant in situ, 1 control scan).

104

105 **Procedure**

106 The non-functioning Cochlear™ CI612 was prepared for scanning by separating and electrically
107 isolating the two protruding electrode arrays using electrical tape. CI positions were standardised
108 across participants using an adult silicone swimming cap which had been marked in permanent ink
109 by an experienced ENT surgeon to reflect four viable sites for surgical placement of the internal CI
110 component on each side of the head. The participant was fitted with earplugs for the attenuation of
111 acoustic noise, and asked to wear the swimming cap. The fit of the cap was checked and adjusted to
112 ensure that the markings were symmetrical, i.e. that the centre line of the swimming cap exactly
113 followed the nasion toinion line on the participant. A 10-20 positioning system was attempted, but
114 the shape of the cap meant that there was very little margin for movement in the forward-backward
115 pitch of the cap. The position of each implant site was checked and determined to be on the skull.
116 The distance between the magnet and the outer ear canal was 8.5 cm, 9.5 cm, 7.5 cm, and 6.5 cm
117 (Figure 1), using a procedure similar to Todt et al [16]. The participant was then made comfortable in
118 the scanner and the first T1 FFE scan acquired as a control. Following this, the scanner bed was
119 moved out of the scanner and the participant allowed to lift their head such that the CI 612 could be
120 placed in the first drawn position underneath the swimming cap. At this point the participant was
121 asked if they experienced any sensation around the area of the implant, and whether there was any
122 discomfort, heating, vibration, or any other sensation associated with the implant. The participant
123 was then asked to return to the same position/orientation as previously and the scanner bed was
124 returned to the same position and a second T1 FFE scan acquired. This procedure was repeated for
125 each of the eight CI positions producing a total of nine T1 FFE scans. Figure 1 shows the positions of
126 the CI locations on the swim cap.

127

128 **Image pre-processing and analysis**

129 Image pre-processing was performed using Statistical Parametric Mapping (SPM) version 12
130 (Wellcome Trust Centre for Neuroimaging, UK) and in-house software coded in MATLAB. Motion
131 correction was performed in SPM12 to counteract the effect of the participant's head position
132 differing between each acquisition due to lifting and replacing the head while placing or moving the
133 CI. To improve the efficacy of the motion correction, a weighting image was used such that the
134 motion correction software favoured information from areas that were unaffected by the presence
135 of the implant in any image. This weighting image was calculated by taking the sum of the eight
136 images where the implant was present, then thresholding this at an image intensity of 5000
137 (approximately the maximum signal intensity in images unaffected by artefact).

138

139 The motion-corrected images were then warped into standardised MNI space (Montreal
140 Neurological Institute, Montreal, Canada) using SPM's normalization tool. Co-registration between
141 the individual participant space and MNI space was performed using each participant's control
142 image acquired before the CI was placed under the swimming cap, generating a transformation
143 matrix. This transformation matrix was subsequently applied to all other motion-corrected images
144 on an individual basis.

145

146 Control images (i.e. those with no CI present) were then segmented using SPM's segmentation tool,
147 which provides tissue masks of grey matter, white matter, cerebrospinal fluid (CSF), bone and scalp.
148 For each participant, the components containing grey matter, white matter, CSF and bone were
149 summed, and re-thresholded at 1, to provide a binary mask of the entire head, without any artefact
150 present. Each artefact image was then thresholded at an image intensity of 100 (the approximate
151 signal of the CSF in the ventricles) and multiplied by that subject's binary control mask to give a
152 binary mask of each artefact. To account for the variation in head size between participants, the size
153 of the artefact (number of voxels in this artefact image) was expressed as a percentage of the total
154 intracranial volume (number of voxels in the control image).

155

156 **Radiological evaluation of the diagnostic impact of artefacts**

157 To evaluate the diagnostic implications of the induced artefacts, two clinical radiologists with
158 experience in brain MRI evaluation rated the presence of the artefact and the likely impact on the
159 detection of pathology independently for 20 radiological brain anatomical locations (Figure 4).
160 Unprocessed images were viewed using the RadiAnt DICOM Viewer 2020.2 [18]. The radiologists was
161 asked to evaluate each location for the likely impact of artefact on the ability to identify pathology
162 according to the following scale four point scale: (0) very unlikely to miss any abnormality, (1) a

163 subtle abnormality would be missed, (2) a moderate abnormality would be missed, and (3) a gross
164 abnormality would be missed. Artefacts were then classified as one or more of the following types:
165 (a) signal drop-out; (b) signal pile-up; (c) banding (large signal losses in bands); (d) rippling (smaller
166 signal losses in ripples); (e) spatial distortion/warping; or (f) other, for which a free text description
167 could be provided by the rater.

168

169 To assess the image usability, the modal rating of impact on the identification of pathology attained
170 for each position of the CI and each brain region was calculated across raters and then across
171 participants.

172

173 **Statistical analyses**

174 Repeated-measures analysis of covariance (ANOVA) was used to compare relative artefact volumes
175 between individuals and between the 8 CI positions separately using SPSS version 26 (IBM, NY, USA).

176 To assess inter-rater agreement for the radiological evaluations, a quadratic-weighted Cohen's
177 Kappa was used in MedCalc for Windows, version 19.5.3 (MedCalc Software, Ostend, Belgium).

178

179 **Results**

180 **Safety and tolerability**

181 Upon asking whether participants experienced any sensation at the site of the device during
182 scanning, no participant stated any adverse effects from the presence of the implant in any position.

183 They all reported being unaware of the presence of the device, with the exception that they
184 reported feeling and/or hearing "clicking" from the rotating retaining magnet as the implant was
185 moved from site to site, or the participant was moved in and out of the scanner, between scans.

186

187 **Quantification of artefact for different CI locations**

188 Image co-registration outputs reported that the average displacement from the control image was
189 5.9 mm, with the maximum being 17.7 mm. The greatest rotational displacement of any image from
190 the control image was less than 0.2°. Figure 2 shows the extent of the CI artefact for each of the
191 eight positions (4 left, 4 right), and the relative artefact size and overlap in each of the three
192 participants (raw data in supplemental material). Figure 3 shows the relative size of the CI artefact as
193 a percentage of the total head size, in voxels. The artefact in positions 4 and 5 (the most posterior
194 locations) was the smallest by percentage of total head size, but artefact volumes did not differ
195 significantly across the 8 locations ($F_{3,6} = 4.036$; $p = 0.069$). The side on which the implant was
196 positioned did not significantly affect the size of the artefact ($F_{1,2} = 0.028$; $p = 0.882$).

197

198 **Radiological evaluation of diagnostic impact of artefacts for different CI locations**

199 There was statistically “substantial” inter-rater agreement (as signified by a Quadratic Weighted
200 Cohen’s κ of between 0.61 and 0.80) on the impact of artefacts on the diagnostic utility of the
201 images from all three participants (See Table 1). Figure 4 shows the modal rating attributed to each
202 brain region and each CI location across raters and participants, representing the severity of the
203 degree to which the artefact impacts the usefulness of the images. As the position of the CI was
204 moved from most anterior to most posterior (i.e. left-most to medial and right-most to medial, see
205 Figure 1), the number of total regions that were rated as potentially obscuring either a moderate or
206 gross abnormality was lowest for the most anterior and most posterior CI positions, and highest for
207 the positions in the middle of the range. Temporal, occipital, and parietal regions ipsilateral to the
208 implant were severely affected by the CI in any position, whereas the anterior corpus callosum was
209 relatively unaffected by the CI in any position. The frontal lobe, hippocampus, deep grey matter, and
210 midbrain ipsilateral to the CI, as well as the posterior corpus callosum, were less affected when the
211 CI was placed in posterior-most positions. Conversely, the ipsilateral cerebellum, pons and medulla
212 were less affected when the implant was placed in more anterior positions.

213

214 The likelihood of missing pathology was associated significantly with signal dropout, which occurred
215 30% of the time ($r = 0.71$, $p < 0.05$), signal pileup (prevalence = 26%; $r = 0.59$, $p < 0.05$), banding
216 (prevalence = 12%; $r = 0.29$, $p < 0.05$), and distortion (prevalence = 2%; $r = 0.07$, $p < 0.05$). The
217 presence of rippling (prevalence = 16%) was not found to be strongly correlated with the likelihood
218 of missing pathology ($r = 0.03$; $p > 0.1$).

219

220 **Discussion**

221 The present work was motivated by the needs of patients who are implanted with a CI while having
222 a known co-morbidity that would benefit from regular monitoring with MRI such as NF2. Surgical
223 removal and reinsertion of the implant magnet may have a cumulative detrimental impact on the
224 scalp in the region of the implant and will not be practicable to perform indefinitely. As
225 demonstrated in these findings, there is significant inter-subject variation in the impact of the
226 implant location on the image artefact. This may be due to (a) differences in CI placement, which
227 were carefully controlled for in the procedure; (b) inter-subject anatomical differences, which would
228 be accounted for by alignment of the images, but any transformation, such as that into MNI space,
229 would emphasise any differences in head size; or (c) the impact on the excitation efficiency of small
230 differences in the orientation of the participant’s head (and therefore the implant) relative to the

231 scanner magnetic field, which were only somewhat accounted for by consistent placement of the
232 participant in the scanner. This inter-subject variability highlights the need for future studies to
233 consider such inter-subject variations and other sources of variability and demonstrates the utility
234 and importance of addressing implant site on a per-subject basis. The selection of a surgical site
235 based on pre-operative evaluation of artefact distribution as described here could have long-term
236 benefits in allowing optimal imaging of certain brain regions without the need for regular surgical
237 intervention. As demonstrated in the current study, a comprehensive assessment of surgical options
238 can be performed within an hour by an appropriately trained radiographic technologist with no
239 adverse effects on the patient.

240

241 While the current study suggests it may not be feasible to image temporal, occipital, and parietal
242 regions ipsilateral to the CI in any position, anatomical locations contralateral to the CI were
243 generally much less severely affected, and the anterior corpus callosum was relatively unaffected by
244 the CI in any position. An effect of anterior versus posterior CI placement was also observed such
245 that posterior positions for the CI were associated with the lowest levels of artefact affecting the
246 ipsilateral frontal lobe, hippocampus, deep grey matter and midbrain, and this information could be
247 useful for planning CI placement in the presence of known lesions at these sites. For example, if a
248 pre-implantation patient has a frontal meningioma on the side of planned implantation, then the
249 more posterior CI positions (4 or 5, depending on side) would be most appropriate to reduce the
250 chance of artefacts limiting the MRI follow-up of the meningioma. Conversely, if a known lesion
251 involves the ipsilateral cerebellum, pons, or medulla are to be monitored, then the CI should be
252 positioned more anteriorly , as a lesser degree of artefact was observed in these anatomical areas
253 with CI positions 1 and 8.

254

255 The current study used only one image type (a 3D-T1-weighted sequence acquired at 1.5 mm³, with
256 a TE of 1.52 ms and a bandwidth of 285 Hz) to allow demonstration of proof-of-principle for this
257 approach while maintaining an acceptable scan duration. In clinical practice the choice of MRI
258 sequences obtained will depend on indications for the scan, and therefore the impact of the artefact
259 on the diagnostic quality of the scan will vary with sequence selection. The use of a single sequence
260 in this work limits the generalisability of our findings, as does the choice to use a sequence that is
261 not compatible with MARS [19] or additions such as SEMAC (slice encoding for metal artifact
262 correction) [20], which have been shown to significantly reduce the extent of the artefact, and
263 increase the proportion of images that are usable [5]. These design choices were made to keep the
264 length of the scanning protocol (comprising nine repetitions of the chosen sequence) to a

265 reasonable total duration for participants. We plan to extend the current work to map the artefact
266 distribution and impact on diagnostic quality for other diagnostic imaging sequences commonly used
267 in clinical neuroimaging. For example, the internal auditory meatus and membranous inner ear
268 structures are typically assessed using heavily T2-weighted high-resolution sequences employing
269 balanced steady-state acquisition, such as (FIESTA) or constructive interference in steady state
270 (CISS). In addition, when monitoring the growth of ipsilateral or contralateral vestibular
271 schwannomas or other intracranial manifestations associated with NF2, such as meningiomas, T1-
272 weighted images with and without the injection of gadolinium contrast are typically used. [3D](#)
273 [sequences are often favoured for clinical brain imaging because they facilitate rapid imaging of the](#)
274 [whole brain volume providing thin slices for post-acquisition multi-planar reformatting. However, 3D](#)
275 [sequences and sequences with thick slices can be more vulnerable to magnetic field](#)
276 [inhomogeneities, such as those induced by metal, evident in through-plane geometric distortions.](#)
277 [For this reason, 2D sequences with thin slices and other MARS implementations may provide images](#)
278 [with less distortion, but at great time penalty.](#) More generally in clinical brain imaging, certain
279 commonly used sequences such as echo planar based diffusion weighted imaging and GE-based
280 susceptibility weighted imaging sequences are more substantially affected by artefacts induced by
281 metallic implants. Understanding the distribution of CI-induced artefacts for these commonly used
282 clinical sequences will be valuable when considering device placement for CI candidates who are
283 likely to need follow-up MRI.

284

285 While the majority of patients who are CI users will be scanned at the lower field strength of 1.5 T,
286 the present study was conducted using a 3.0 T scanner to demonstrate the approach using the new
287 generation of CIs featuring retaining magnets that can be safely scanned at 3.0 T. The current study
288 demonstrates the feasibility and utility of pre-operative surveys to inform surgical planning in
289 patients where routine MRI acquisition is anticipated or indicated. As the procedures described in
290 this article were well tolerated and presented no adverse effects in healthy volunteers, further
291 development and evaluation of a clinical protocol for mapping CI-induced artefact in individual pre-
292 implantation patients is warranted, including assessing the impact of head orientation on image
293 quality.

294

295 **Conclusion**

296 This study observed the effect of CI location on image quality and usability, for a high bandwidth,
297 short TE, T1-weighted FFE (GE) scan, while controlling for inter-individual anatomical differences by
298 scanning individuals wearing a swim cap with a non-functional CI placed underneath. This approach

299 was well tolerated, and a similar method of investigation could be performed for clinical purposes in
300 a candidate for CI surgery, prior to implantation, to inform surgical planning. While implant position
301 did not affect the visibility of brain regions such as the frontal, temporal, and parietal lobes
302 contralateral to the CI, it did impact other regions. Posterior CI positions should be favoured to
303 preserve the ability to image the frontal lobe, hippocampus, deep grey matter, and midbrain
304 ipsilateral to the CI, whereas anterior positions favour the ipsilateral cerebellum, pons, and medulla.
305

306 **Abbreviations**

307 FFE = fast-field echo; GE = gradient echo; IAM = internal auditory meatus; MRI = magnetic resonance
308 imaging; NF2 = neurofibromatosis type 2
309

310 **References**

- 311 1. Tam YC, Lee JWY, Gair J, Jackson C, Donnelly NP, Tysome JR, Axon PR, Bance ML.
312 Performing MRI Scans on Cochlear Implant and Auditory Brainstem Implant Recipients: Review of
313 14.5 Years Experience. *Otol Neurotol*. 2020 Jun;41(5):e556-e562. doi:
314 10.1097/MAO.0000000000002569.
- 315 2. Walton J, et al. MRI without magnet removal in neurofibromatosis type 2 patients with cochlear
316 and auditory brainstem implants. *Otol Neurotol*. 2014 Jun;35(5):821-5.
- 317 3. Edmonson HA, et al. MR Imaging and Cochlear Implants with Retained Internal Magnets: Reducing
318 Artifacts near Highly Inhomogeneous Magnetic Fields. *Radiographics*. 2018 Jan-Feb;38(1):94-106.
- 319 4. Talbot BS, Weinberg EP. MR Imaging with Metal-suppression Sequences for Evaluation of Total
320 Joint Arthroplasty. *Radiographics*. 2016 Jan-Feb;36(1):209-25.
- 321 5. Shah S, Padormo F, Knott K, Thomson S, Conner S, Charles-Edwards G, Touska P. Imaging the
322 Internal Acoustic Meatus (IAMs) of patients with cochlear implants in-situ using Slice Encoded Metal
323 Artefact Reduction. *Proceedings of the International Society for Magnetic Resonance in Medicine*,
324 2020, abstract number 3411.
- 325 6. Tolisano AM, Baumgart B, Whitson J, Kutz JW Jr. Cochlear implantation in patients with
326 neurofibromatosis type 2. *Otol Neurotol*. 2019 Apr;40(4):e381-e385. doi:
327 10.1097/MAO.0000000000002165
- 328 7. Lustig LR, Yeagle J, Driscoll CL, Blevins N, Francis H, Niparko JK. Cochlear implantation in patients
329 with neurofibromatosis type 2 and bilateral vestibular schwannoma. *Otol Neurotol*. 2006
330 Jun;27(4):512-8. doi: 10.1097/01.mao.0000217351.86925.51. PMID: 16791043.

331 8. Tan H, Jia H, Li Y, Zhang Z, Zhu W, Cai Y, Wang Z, Wu H. Impact of cochlear implantation on the
332 management strategy of patients with neurofibromatosis type 2. *Eur Arch Otorhinolaryngol*. 2018
333 Nov;275(11):2667-2674. doi: 10.1007/s00405-018-5127-9. Epub 2018 Sep 18. PMID: 30229456

334 9. Carlson ML, Breen JT, Driscoll CL, Link MJ, Neff BA, Gifford RH, Beatty CW. Cochlear implantation
335 in patients with neurofibromatosis type 2: variables affecting auditory performance. *Otol Neurotol*.
336 2012 Jul;33(5):853-62. doi: 10.1097/MAO.0b013e318254fba5

337 10. Lloyd SK, Evans DG. Neurofibromatosis type 2 service delivery in England. *Neurosurgery*
338 Volume 64, Issue 5 , November 2018 , Pages 375-380. Doi: 10.1016/j.neuchi.2015.10.006

339 11. Fletcher KT, Horrell EMW, Ayugi J, Irungu C, Muthoka M, Creel LM, Lester C, Bush ML. The
340 Natural History and Rehabilitative Outcomes of Hearing Loss in Congenital Cytomegalovirus: A
341 Systematic Review. *Otol Neurotol*. 2018 Aug;39(7):854-864. doi: 10.1097/MAO.0000000000001861

342 12. Busi M, Rosignoli M, Castiglione A, Minazzi F, Trevisi P, Aimoni C, Calzolari F, Granieri E, Martini
343 A. Cochlear Implant Outcomes and Genetic Mutations in Children with Ear and Brain Anomalies.
344 *Biomed Res Int*. 2015;2015:696281. doi: 10.1155/2015/696281.

345 13. Yamamoto N, Okuyama H, Hiraumi H, Sakamoto T, Matsuura H, Ito J. The Outcome of Cochlear
346 Implantation for Mitochondrial Disease Patients With Syndromic Hearing Loss. *Otol Neurotol*. 2015
347 Sep;36(8):e129-33. doi: 10.1097/MAO.0000000000000817

348 14. Wieser S, Igerc I, Hausegger K, Eckel H. Worldwide 1st MED-EL Mi1200 SYNCHRONY cochlear
349 implant magnet removal for MRI image artifact reduction. *Otolaryngology Case Reports*, Volume 9,
350 November 2018, Pages 41-44. <https://doi.org/10.1016/j.xocr.2018.11.002> .

351 15. Wagner F, Wimmer W, Leidolt L, Vischer M, Weder S, Wiest R, Mantokoudis G, Caversaccio MD.
352 Significant Artifact Reduction at 1.5T and 3T MRI by the Use of a Cochlear Implant with Removable
353 Magnet: An Experimental Human Cadaver Study. *PLoS One*. 2015 Jul 22;10(7):e0132483. doi:
354 10.1371/journal.pone.0132483. eCollection 2015. PMID: 26200775

355 16. Todt, Ingo; Rademacher, Grit; Mittmann, Philipp; Wagner, Jan; Mutze, Sven; Ernst, Arne. MRI
356 Artifacts and Cochlear Implant Positioning at 3 T In Vivo. *Otology & Neurotology*: July 2015 - Volume
357 36 - Issue 6 - p 972-976. doi: 10.1097/MAO.0000000000000720

358 17. Ay N, Todt I, Sudhoff H. Effects of head position on cochlear implant MRI artifacts at 3 T in vivo.
359 *Laryngo-Rhino-Otol* 2019; 98(S 02): S214. DOI: 10.1055/s-0039-1685662.

360 18. Medixant. RadiAnt DICOM Viewer [Software]. Version 2020.2. Jul 19, 2020. URL:
361 <https://www.radiantviewer.com>

362 19. Olsen RV, et al. Metal artifact reduction sequence: early clinical applications. *Radiographics*. 2000
363 May-Jun;20(3):699-712.

364 20. Lu W, Pauly KB, Gold GE, Pauly JM, Hargreaves BA. SEMAC: Slice Encoding for Metal Artifact
365 Correction in MRI. *Magn Reson Med.* 2009 Jul; 62(1): 66–76.
366

367 **Figures**

368

369 Figure 1: A photograph of the CI positions as drawn onto a swim cap by an ENT surgeon experienced
370 in cochlear implantation. The CI was placed underneath each outline in turn for the acquisition of an
371 MR image in each participant. [Permission to use the image has been obtained from the subject.]

372

373 Figure 2: Extent of the CI artefact for each of the eight positions. Artefact extent was used to form a
374 binary mask. Coloured areas represent the number of participants (out of three) for whom that area
375 was obscured by image artefact generated by the CI. Bottom row shows the mathematical union of
376 all four positions on the left and right of the head, respectively. Images shown are in conventional
377 view (i.e. from below) and in MNI space. See supplemental material for raw images.

378

379 Figure 3: The relative artefact size, in terms of the percentage of the total head size in each of the
380 three participants and at each CI position. Positions 1 and 8 were the most anterior, positions 4 and
381 5 the most posterior. Red vertical bars represent the mean across three participants for each
382 position.

383

384 Figure 4: Radiological evaluation of artefact; impact of artefact on likely detection of abnormalities
385 for each of the 20 brain regions as shown by the modal rating across raters and participants. Higher
386 values, and red shading, indicate higher likelihood of an abnormality being missed by radiological
387 evaluation, whereas lower/blue indicates a comparatively low likelihood of missing pathology. It is
388 worth noting that there was a mode 9 brain regions out of 20 (range 7 to 14) that were deemed
389 unlikely to impact the identification of pathology across all CI locations.

390

391 **Tables**

392

393 Table 1: Absolute agreement between raters in terms of the number of disagreements with a
394 difference of more than 1 point on the scale, and Quadratic-Weighted Cohen's κ with 95%
395 confidence intervals. Percentage of disagreements based on a total number of 180 ratings (20 brain
396 regions across 8 CI locations and the control image).

1 **Parametric assessment of the effect of cochlear implant positioning** 2 **on brain MRI artefacts at 3 Tesla**

3

4 **Abstract**

5 **Background:** Brain magnetic resonance imaging (MRI) in patients with cochlear implants (CIs) is
6 impacted by image artefacts.

7 **Hypothesis:** The optimal positioning of the CI to minimise artefacts is unknown. This study aimed to
8 characterise the dependence of the extent and distribution of the artefact on CI positioning.

9 **Methods:** Three normally-hearing individuals underwent MRI using a standard T1-weighted 3D
10 sequence. Scans were acquired with a non-functioning CI placed underneath a swimming cap at four
11 plausible scalp positions on each side, and without the CI in situ. The artefact in each image was
12 assessed quantitatively using voxel-based techniques. Two radiologists also independently rated the
13 likely impact of the artefact on detection of pathology for 20 neuroradiological locations.

14 **Results:** The procedure was well tolerated. The most postero-inferior CI positions resulted in the
15 smallest apparent artefacts. Radiological evaluations suggested that artefacts would likely limit
16 pathology detection in the ipsilateral temporal, parietal and occipital lobes, regardless of CI location.
17 Pathology detection in contralateral structures and anterior corpus callosum was rarely affected.
18 Certain CI locations appeared to selectively spare ipsilateral structures, e.g., postero-inferior CI
19 locations selectively spared ipsilateral midbrain, deep grey matter, and frontal lobes.

20 **Conclusion:** A CI placed under a swimming cap is a feasible tool for observing the effect of CI
21 location on image usability within a single subject and potentially informing surgical planning.
22 Regardless of CI placement, artefacts involving ipsilateral parietal, temporal and occipital lobes
23 severely limited diagnostic image utility. Between 35% and 70% of neuroradiological features were
24 deemed unaffected by the implant.

25

26

27 **Hypothesis**

28 The optimal positioning of the CI to minimise such artefacts is unknown. This study aimed to
29 characterise the dependence of the extent and distribution of the CI artefact on CI positioning.

30

31 **Introduction**

32 Magnetic resonance imaging (MRI) forms a non-invasive imaging modality that is sensitive to many
33 pathologies, and as such is often the preferred imaging technique for diagnosis and on-going disease
34 evaluation. MRI is widely used in imaging diseases of the brain because the excellent soft tissue
35 contrast and availability of a range of sequences that are sensitive to different pathological
36 processes provide great diagnostic value. A cochlear implant (CI) is a device that provides auditory
37 input for deaf individuals and comprises an implanted component (receiver-stimulator) and an
38 external component (speech/sound processor) worn behind the ear. The implanted component
39 contains a retaining magnet and a hermetically-sealed package with electronics placed under the
40 scalp, and its presence raises MRI safety concerns [1], such as displacement of the internal retaining
41 magnet and unintended acoustic stimulation [2].

42

43 Major manufacturers have revised the design of the implanted magnet to include a rotating
44 component that minimises torque on the CI when it is placed in a magnetic field, thus improving
45 patient comfort during MRI. However, clinical imaging of the head of CI-implanted patients is still
46 confounded by substantial image artefacts caused by both the retaining magnet and the electronic
47 components [3,4]. As a result, MRI is often avoided in this population. Computed tomography (CT)
48 provides an alternative imaging technique that avoids the MRI-related safety concerns, but
49 sensitivity to certain pathologies may not be as good as MRI, and image artefacts due to beam
50 attenuation by the metallic components can also degrade CT images. Metal artefact reduction
51 sequences (MARS) have recently been applied to spin-echo sequences on many scanner systems,
52 but are associated with increased radiofrequency energy and consequently increased scan durations
53 that could limit their utility in certain clinical settings [5].

54

55 Certain medical conditions associated with hearing loss may require regular (e.g. annual) MRI
56 assessment to monitor disease progression. For example, neurofibromatosis type 2 (NF2), is a
57 complex genetic condition that causes benign tumours (schwannomas) to grow along the nerves.
58 Most commonly this affects the vestibular nerves, and while benign, vestibular schwannomas cause
59 hearing loss for which cochlear implantation may be considered as a treatment when the cochlear
60 nerve is anatomically preserved [6,7,8,9]. As annual monitoring of the brain is advised for people

61 with NF2 [10], the ability to safely acquire diagnostic-quality MRI in those with cochlear implants is
62 important. A similar argument can be made for children with congenital disorders such as
63 congenital cytomegalovirus infection or neurogenetic / mitochondrial disorders associated with
64 deafness that may benefit from cochlear implantation [11,12,13], for which on-going MRI studies
65 may be important for monitoring the associated brain disease. Furthermore, as cochlear
66 implantation becomes widespread, MRI will become more important for diagnosing and monitoring
67 unrelated, acquired brain pathologies in CI-implanted patients.

68

69 Removal of the retaining magnet is an effective method of reducing image artefacts due to CIs
70 [14,15]. However, this approach requires the patient to undergo additional surgical procedures
71 before and after each scan and may impose a period of auditory deprivation while wounds heal.
72 Non-invasive methods of minimising the CI artefact would therefore significantly minimise patient
73 burden in cases where regular brain MRI is indicated and address potential barriers preventing this
74 patient group from benefitting from MRI imaging. Both the position of the CI implantation site [16]
75 and the orientation of the head in the MR scanner [17] affect which regions of the image are
76 affected by artefact and which anatomical features are visible. This study aimed to develop an
77 approach to allow the evaluation of CI artefacts as the position of the implantable component is
78 varied parametrically across different scalp positions. We demonstrate the utility of using a non-
79 functioning CI device placed at 8 plausible surgical positions on the scalp of healthy volunteers by
80 evaluating the extent and distribution of the CI artefact, and its impact on the diagnostic quality of a
81 T1-weighted structural brain MRI sequence.

82

83 **Materials and Methods**

84 **Participants**

85 No formal sample size calculations were performed owing to the exploratory nature of the study
86 activities. Experimental procedures conformed to the World Medical Association's Declaration of
87 Helsinki and were approved by the University Faculty of Medicine and Health Sciences Research
88 Ethics Committee (reference: 460-2001). All participants gave written informed consent. Participants
89 were 23, 30 and 34 years old. Two of the participants were female.

90

91 **Image acquisition**

92 MRI data were acquired on a Philips 3.0 T Achieva MR scanner (Philips Healthcare, Best,
93 Netherlands) using a 32-channel SENSE head coil. The scanner provided the MR conditional
94 requirements for the Cochlear CI 612 implant by imposing the indicated safe performance limits

95 (ScanWise Implant, Philips Healthcare). Data were collected using a standard 3D-T1-weighted
96 acquisition, taken from the manufacturer's defaults, so that it would be analogous to what would be
97 used in the clinical setting, and would ensure that the extent of the artefact was not
98 underestimated. The sequence used a steady-state (fast-field echo; FFE) gradient echo (GE)
99 acquisition at 1.5 mm isotropic spatial resolution, reconstructed to 1 mm isotropic; field of view of
100 240×240×160 mm³, echo time (TE) of 1.52 ms; repetition time (TR) of 25 ms, flip angle = 30°;
101 bandwidth = 285 Hz, and sensitivity encoding (SENSE) factor 1.6. A stack comprising 150 contiguous
102 sagittal slices provided whole-head coverage. The acquisition had a SAR of 0.484 Wkg⁻¹, took 2 min
103 57 s and was repeated nine times on each participant (8 scans with implant in situ, 1 control scan).

104

105 **Procedure**

106 The non-functioning Cochlear™ CI612 was prepared for scanning by separating and electrically
107 isolating the two protruding electrode arrays using electrical tape. CI positions were standardised
108 across participants using an adult silicone swimming cap which had been marked in permanent ink
109 by an experienced ENT surgeon to reflect four viable sites for surgical placement of the internal CI
110 component on each side of the head. The participant was fitted with earplugs for the attenuation of
111 acoustic noise, and asked to wear the swimming cap. The fit of the cap was checked and adjusted to
112 ensure that the markings were symmetrical, i.e. that the centre line of the swimming cap exactly
113 followed the nasion toinion line on the participant. A 10-20 positioning system was attempted, but
114 the shape of the cap meant that there was very little margin for movement in the forward-backward
115 pitch of the cap. The position of each implant site was checked and determined to be on the skull.
116 The distance between the magnet and the outer ear canal was 8.5 cm, 9.5 cm, 7.5 cm, and 6.5 cm
117 (Figure 1), using a procedure similar to Todt et al [16]. The participant was then made comfortable in
118 the scanner and the first T1 FFE scan acquired as a control. Following this, the scanner bed was
119 moved out of the scanner and the participant allowed to lift their head such that the CI 612 could be
120 placed in the first drawn position underneath the swimming cap. At this point the participant was
121 asked if they experienced any sensation around the area of the implant, and whether there was any
122 discomfort, heating, vibration, or any other sensation associated with the implant. The participant
123 was then asked to return to the same position/orientation as previously and the scanner bed was
124 returned to the same position and a second T1 FFE scan acquired. This procedure was repeated for
125 each of the eight CI positions producing a total of nine T1 FFE scans. Figure 1 shows the positions of
126 the CI locations on the swim cap.

127

128 **Image pre-processing and analysis**

129 Image pre-processing was performed using Statistical Parametric Mapping (SPM) version 12
130 (Wellcome Trust Centre for Neuroimaging, UK) and in-house software coded in MATLAB. Motion
131 correction was performed in SPM12 to counteract the effect of the participant's head position
132 differing between each acquisition due to lifting and replacing the head while placing or moving the
133 CI. To improve the efficacy of the motion correction, a weighting image was used such that the
134 motion correction software favoured information from areas that were unaffected by the presence
135 of the implant in any image. This weighting image was calculated by taking the sum of the eight
136 images where the implant was present, then thresholding this at an image intensity of 5000
137 (approximately the maximum signal intensity in images unaffected by artefact).

138

139 The motion-corrected images were then warped into standardised MNI space (Montreal
140 Neurological Institute, Montreal, Canada) using SPM's normalization tool. Co-registration between
141 the individual participant space and MNI space was performed using each participant's control
142 image acquired before the CI was placed under the swimming cap, generating a transformation
143 matrix. This transformation matrix was subsequently applied to all other motion-corrected images
144 on an individual basis.

145

146 Control images (i.e. those with no CI present) were then segmented using SPM's segmentation tool,
147 which provides tissue masks of grey matter, white matter, cerebrospinal fluid (CSF), bone and scalp.
148 For each participant, the components containing grey matter, white matter, CSF and bone were
149 summed, and re-thresholded at 1, to provide a binary mask of the entire head, without any artefact
150 present. Each artefact image was then thresholded at an image intensity of 100 (the approximate
151 signal of the CSF in the ventricles) and multiplied by that subject's binary control mask to give a
152 binary mask of each artefact. To account for the variation in head size between participants, the size
153 of the artefact (number of voxels in this artefact image) was expressed as a percentage of the total
154 intracranial volume (number of voxels in the control image).

155

156 **Radiological evaluation of the diagnostic impact of artefacts**

157 To evaluate the diagnostic implications of the induced artefacts, two clinical radiologists with
158 experience in brain MRI evaluation rated the presence of the artefact and the likely impact on the
159 detection of pathology independently for 20 radiological brain anatomical locations (Figure 4).
160 Unprocessed images were viewed using the RadiAnt DICOM Viewer 2020.2 [18]. The radiologists was
161 asked to evaluate each location for the likely impact of artefact on the ability to identify pathology
162 according to the following scale four point scale: (0) very unlikely to miss any abnormality, (1) a

163 subtle abnormality would be missed, (2) a moderate abnormality would be missed, and (3) a gross
164 abnormality would be missed. Artefacts were then classified as one or more of the following types:
165 (a) signal drop-out; (b) signal pile-up; (c) banding (large signal losses in bands); (d) rippling (smaller
166 signal losses in ripples); (e) spatial distortion/warping; or (f) other, for which a free text description
167 could be provided by the rater.

168

169 To assess the image usability, the modal rating of impact on the identification of pathology attained
170 for each position of the CI and each brain region was calculated across raters and then across
171 participants.

172

173 **Statistical analyses**

174 Repeated-measures analysis of covariance (ANOVA) was used to compare relative artefact volumes
175 between individuals and between the 8 CI positions separately using SPSS version 26 (IBM, NY, USA).

176 To assess inter-rater agreement for the radiological evaluations, a quadratic-weighted Cohen's
177 Kappa was used in MedCalc for Windows, version 19.5.3 (MedCalc Software, Ostend, Belgium).

178

179 **Results**

180 **Safety and tolerability**

181 Upon asking whether participants experienced any sensation at the site of the device during
182 scanning, no participant stated any adverse effects from the presence of the implant in any position.

183 They all reported being unaware of the presence of the device, with the exception that they
184 reported feeling and/or hearing "clicking" from the rotating retaining magnet as the implant was
185 moved from site to site, or the participant was moved in and out of the scanner, between scans.

186

187 **Quantification of artefact for different CI locations**

188 Image co-registration outputs reported that the average displacement from the control image was
189 5.9 mm, with the maximum being 17.7 mm. The greatest rotational displacement of any image from
190 the control image was less than 0.2°. Figure 2 shows the extent of the CI artefact for each of the
191 eight positions (4 left, 4 right), and the relative artefact size and overlap in each of the three
192 participants (raw data in supplemental material). Figure 3 shows the relative size of the CI artefact as
193 a percentage of the total head size, in voxels. The artefact in positions 4 and 5 (the most posterior
194 locations) was the smallest by percentage of total head size, but artefact volumes did not differ
195 significantly across the 8 locations ($F_{3,6} = 4.036$; $p = 0.069$). The side on which the implant was
196 positioned did not significantly affect the size of the artefact ($F_{1,2} = 0.028$; $p = 0.882$).

197

198 **Radiological evaluation of diagnostic impact of artefacts for different CI locations**

199 There was statistically “substantial” inter-rater agreement (as signified by a Quadratic Weighted
200 Cohen’s κ of between 0.61 and 0.80) on the impact of artefacts on the diagnostic utility of the
201 images from all three participants (See Table 1). Figure 4 shows the modal rating attributed to each
202 brain region and each CI location across raters and participants, representing the severity of the
203 degree to which the artefact impacts the usefulness of the images. As the position of the CI was
204 moved from most anterior to most posterior (i.e. left-most to medial and right-most to medial, see
205 Figure 1), the number of total regions that were rated as potentially obscuring either a moderate or
206 gross abnormality was lowest for the most anterior and most posterior CI positions, and highest for
207 the positions in the middle of the range. Temporal, occipital, and parietal regions ipsilateral to the
208 implant were severely affected by the CI in any position, whereas the anterior corpus callosum was
209 relatively unaffected by the CI in any position. The frontal lobe, hippocampus, deep grey matter, and
210 midbrain ipsilateral to the CI, as well as the posterior corpus callosum, were less affected when the
211 CI was placed in posterior-most positions. Conversely, the ipsilateral cerebellum, pons and medulla
212 were less affected when the implant was placed in more anterior positions.

213

214 The likelihood of missing pathology was associated significantly with signal dropout, which occurred
215 30% of the time ($r = 0.71$, $p < 0.05$), signal pileup (prevalence = 26%; $r = 0.59$, $p < 0.05$), banding
216 (prevalence = 12%; $r = 0.29$, $p < 0.05$), and distortion (prevalence = 2%; $r = 0.07$, $p < 0.05$). The
217 presence of rippling (prevalence = 16%) was not found to be strongly correlated with the likelihood
218 of missing pathology ($r = 0.03$; $p > 0.1$).

219

220 **Discussion**

221 The present work was motivated by the needs of patients who are implanted with a CI while having
222 a known co-morbidity that would benefit from regular monitoring with MRI such as NF2. Surgical
223 removal and reinsertion of the implant magnet may have a cumulative detrimental impact on the
224 scalp in the region of the implant and will not be practicable to perform indefinitely. As
225 demonstrated in these findings, there is significant inter-subject variation in the impact of the
226 implant location on the image artefact. This may be due to (a) differences in CI placement, which
227 were carefully controlled for in the procedure; (b) inter-subject anatomical differences, which would
228 be accounted for by alignment of the images, but any transformation, such as that into MNI space,
229 would emphasise any differences in head size; or (c) the impact on the excitation efficiency of small
230 differences in the orientation of the participant’s head (and therefore the implant) relative to the

231 scanner magnetic field, which were only somewhat accounted for by consistent placement of the
232 participant in the scanner. This inter-subject variability highlights the need for future studies to
233 consider such inter-subject variations and other sources of variability and demonstrates the utility
234 and importance of addressing implant site on a per-subject basis. The selection of a surgical site
235 based on pre-operative evaluation of artefact distribution as described here could have long-term
236 benefits in allowing optimal imaging of certain brain regions without the need for regular surgical
237 intervention. As demonstrated in the current study, a comprehensive assessment of surgical options
238 can be performed within an hour by an appropriately trained radiographic technologist with no
239 adverse effects on the patient.

240

241 While the current study suggests it may not be feasible to image temporal, occipital, and parietal
242 regions ipsilateral to the CI in any position, anatomical locations contralateral to the CI were
243 generally much less severely affected, and the anterior corpus callosum was relatively unaffected by
244 the CI in any position. An effect of anterior versus posterior CI placement was also observed such
245 that posterior positions for the CI were associated with the lowest levels of artefact affecting the
246 ipsilateral frontal lobe, hippocampus, deep grey matter and midbrain, and this information could be
247 useful for planning CI placement in the presence of known lesions at these sites. For example, if a
248 pre-implantation patient has a frontal meningioma on the side of planned implantation, then the
249 more posterior CI positions (4 or 5, depending on side) would be most appropriate to reduce the
250 chance of artefacts limiting the MRI follow-up of the meningioma. Conversely, if a known lesion
251 involves the ipsilateral cerebellum, pons, or medulla are to be monitored, then the CI should be
252 positioned more anteriorly , as a lesser degree of artefact was observed in these anatomical areas
253 with CI positions 1 and 8.

254

255 The current study used only one image type (a 3D-T1-weighted sequence acquired at 1.5 mm³, with
256 a TE of 1.52 ms and a bandwidth of 285 Hz) to allow demonstration of proof-of-principle for this
257 approach while maintaining an acceptable scan duration. In clinical practice the choice of MRI
258 sequences obtained will depend on indications for the scan, and therefore the impact of the artefact
259 on the diagnostic quality of the scan will vary with sequence selection. The use of a single sequence
260 in this work limits the generalisability of our findings, as does the choice to use a sequence that is
261 not compatible with MARS [19] or additions such as SEMAC (slice encoding for metal artifact
262 correction) [20], which have been shown to significantly reduce the extent of the artefact, and
263 increase the proportion of images that are usable [5]. These design choices were made to keep the
264 length of the scanning protocol (comprising nine repetitions of the chosen sequence) to a

265 reasonable total duration for participants. We plan to extend the current work to map the artefact
266 distribution and impact on diagnostic quality for other diagnostic imaging sequences commonly used
267 in clinical neuroimaging. For example, the internal auditory meatus and membranous inner ear
268 structures are typically assessed using heavily T2-weighted high-resolution sequences employing
269 balanced steady-state acquisition, such as (FIESTA) or constructive interference in steady state
270 (CISS). In addition, when monitoring the growth of ipsilateral or contralateral vestibular
271 schwannomas or other intracranial manifestations associated with NF2, such as meningiomas, T1-
272 weighted images with and without the injection of gadolinium contrast are typically used. 3D
273 sequences are often favoured for clinical brain imaging because they facilitate rapid imaging of the
274 whole brain volume providing thin slices for post-acquisition multi-planar reformatting. However, 3D
275 sequences and sequences with thick slices can be more vulnerable to magnetic field
276 inhomogeneities, such as those induced by metal, evident in through-plane geometric distortions.
277 For this reason, 2D sequences with thin slices and other MARS implementations may provide images
278 with less distortion, but at great time penalty. More generally in clinical brain imaging, certain
279 commonly used sequences such as echo planar based diffusion weighted imaging and GE-based
280 susceptibility weighted imaging sequences are more substantially affected by artefacts induced by
281 metallic implants. Understanding the distribution of CI-induced artefacts for these commonly used
282 clinical sequences will be valuable when considering device placement for CI candidates who are
283 likely to need follow-up MRI.

284

285 While the majority of patients who are CI users will be scanned at the lower field strength of 1.5 T,
286 the present study was conducted using a 3.0 T scanner to demonstrate the approach using the new
287 generation of CIs featuring retaining magnets that can be safely scanned at 3.0 T. The current study
288 demonstrates the feasibility and utility of pre-operative surveys to inform surgical planning in
289 patients where routine MRI acquisition is anticipated or indicated. As the procedures described in
290 this article were well tolerated and presented no adverse effects in healthy volunteers, further
291 development and evaluation of a clinical protocol for mapping CI-induced artefact in individual pre-
292 implantation patients is warranted, including assessing the impact of head orientation on image
293 quality.

294

295 **Conclusion**

296 This study observed the effect of CI location on image quality and usability, for a high bandwidth,
297 short TE, T1-weighted FFE (GE) scan, while controlling for inter-individual anatomical differences by
298 scanning individuals wearing a swim cap with a non-functional CI placed underneath. This approach

299 was well tolerated, and a similar method of investigation could be performed for clinical purposes in
300 a candidate for CI surgery, prior to implantation, to inform surgical planning. While implant position
301 did not affect the visibility of brain regions such as the frontal, temporal, and parietal lobes
302 contralateral to the CI, it did impact other regions. Posterior CI positions should be favoured to
303 preserve the ability to image the frontal lobe, hippocampus, deep grey matter, and midbrain
304 ipsilateral to the CI, whereas anterior positions favour the ipsilateral cerebellum, pons, and medulla.
305

306 **Abbreviations**

307 FFE = fast-field echo; GE = gradient echo; IAM = internal auditory meatus; MRI = magnetic resonance
308 imaging; NF2 = neurofibromatosis type 2
309

310 **References**

- 311 1. Tam YC, Lee JWY, Gair J, Jackson C, Donnelly NP, Tysome JR, Axon PR, Bance ML.
312 Performing MRI Scans on Cochlear Implant and Auditory Brainstem Implant Recipients: Review of
313 14.5 Years Experience. *Otol Neurotol*. 2020 Jun;41(5):e556-e562. doi:
314 10.1097/MAO.0000000000002569.
- 315 2. Walton J, et al. MRI without magnet removal in neurofibromatosis type 2 patients with cochlear
316 and auditory brainstem implants. *Otol Neurotol*. 2014 Jun;35(5):821-5.
- 317 3. Edmonson HA, et al. MR Imaging and Cochlear Implants with Retained Internal Magnets: Reducing
318 Artifacts near Highly Inhomogeneous Magnetic Fields. *Radiographics*. 2018 Jan-Feb;38(1):94-106.
- 319 4. Talbot BS, Weinberg EP. MR Imaging with Metal-suppression Sequences for Evaluation of Total
320 Joint Arthroplasty. *Radiographics*. 2016 Jan-Feb;36(1):209-25.
- 321 5. Shah S, Padormo F, Knott K, Thomson S, Conner S, Charles-Edwards G, Touska P. Imaging the
322 Internal Acoustic Meatus (IAMs) of patients with cochlear implants in-situ using Slice Encoded Metal
323 Artefact Reduction. *Proceedings of the International Society for Magnetic Resonance in Medicine*,
324 2020, abstract number 3411.
- 325 6. Tolisano AM, Baumgart B, Whitson J, Kutz JW Jr. Cochlear implantation in patients with
326 neurofibromatosis type 2. *Otol Neurotol*. 2019 Apr;40(4):e381-e385. doi:
327 10.1097/MAO.0000000000002165
- 328 7. Lustig LR, Yeagle J, Driscoll CL, Blevins N, Francis H, Niparko JK. Cochlear implantation in patients
329 with neurofibromatosis type 2 and bilateral vestibular schwannoma. *Otol Neurotol*. 2006
330 Jun;27(4):512-8. doi: 10.1097/01.mao.0000217351.86925.51. PMID: 16791043.

331 8. Tan H, Jia H, Li Y, Zhang Z, Zhu W, Cai Y, Wang Z, Wu H. Impact of cochlear implantation on the
332 management strategy of patients with neurofibromatosis type 2. *Eur Arch Otorhinolaryngol*. 2018
333 Nov;275(11):2667-2674. doi: 10.1007/s00405-018-5127-9. Epub 2018 Sep 18. PMID: 30229456

334 9. Carlson ML, Breen JT, Driscoll CL, Link MJ, Neff BA, Gifford RH, Beatty CW. Cochlear implantation
335 in patients with neurofibromatosis type 2: variables affecting auditory performance. *Otol Neurotol*.
336 2012 Jul;33(5):853-62. doi: 10.1097/MAO.0b013e318254fba5

337 10. Lloyd SK, Evans DG. Neurofibromatosis type 2 service delivery in England. *Neurosurgery*
338 Volume 64, Issue 5 , November 2018 , Pages 375-380. Doi: 10.1016/j.neuchi.2015.10.006

339 11. Fletcher KT, Horrell EMW, Ayugi J, Irungu C, Muthoka M, Creel LM, Lester C, Bush ML. The
340 Natural History and Rehabilitative Outcomes of Hearing Loss in Congenital Cytomegalovirus: A
341 Systematic Review. *Otol Neurotol*. 2018 Aug;39(7):854-864. doi: 10.1097/MAO.0000000000001861

342 12. Busi M, Rosignoli M, Castiglione A, Minazzi F, Trevisi P, Aimoni C, Calzolari F, Granieri E, Martini
343 A. Cochlear Implant Outcomes and Genetic Mutations in Children with Ear and Brain Anomalies.
344 *Biomed Res Int*. 2015;2015:696281. doi: 10.1155/2015/696281.

345 13. Yamamoto N, Okuyama H, Hiraumi H, Sakamoto T, Matsuura H, Ito J. The Outcome of Cochlear
346 Implantation for Mitochondrial Disease Patients With Syndromic Hearing Loss. *Otol Neurotol*. 2015
347 Sep;36(8):e129-33. doi: 10.1097/MAO.0000000000000817

348 14. Wieser S, Igerc I, Hausegger K, Eckel H. Worldwide 1st MED-EL Mi1200 SYNCHRONY cochlear
349 implant magnet removal for MRI image artifact reduction. *Otolaryngology Case Reports*, Volume 9,
350 November 2018, Pages 41-44. <https://doi.org/10.1016/j.xocr.2018.11.002> .

351 15. Wagner F, Wimmer W, Leidolt L, Vischer M, Weder S, Wiest R, Mantokoudis G, Caversaccio MD.
352 Significant Artifact Reduction at 1.5T and 3T MRI by the Use of a Cochlear Implant with Removable
353 Magnet: An Experimental Human Cadaver Study. *PLoS One*. 2015 Jul 22;10(7):e0132483. doi:
354 10.1371/journal.pone.0132483. eCollection 2015. PMID: 26200775

355 16. Todt, Ingo; Rademacher, Grit; Mittmann, Philipp; Wagner, Jan; Mutze, Sven; Ernst, Arne. MRI
356 Artifacts and Cochlear Implant Positioning at 3 T In Vivo. *Otology & Neurotology*: July 2015 - Volume
357 36 - Issue 6 - p 972-976. doi: 10.1097/MAO.0000000000000720

358 17. Ay N, Todt I, Sudhoff H. Effects of head position on cochlear implant MRI artifacts at 3 T in vivo.
359 *Laryngo-Rhino-Otol* 2019; 98(S 02): S214. DOI: 10.1055/s-0039-1685662.

360 18. Medixant. RadiAnt DICOM Viewer [Software]. Version 2020.2. Jul 19, 2020. URL:
361 <https://www.radiantviewer.com>

362 19. Olsen RV, et al. Metal artifact reduction sequence: early clinical applications. *Radiographics*. 2000
363 May-Jun;20(3):699-712.

364 20. Lu W, Pauly KB, Gold GE, Pauly JM, Hargreaves BA. SEMAC: Slice Encoding for Metal Artifact
365 Correction in MRI. *Magn Reson Med.* 2009 Jul; 62(1): 66–76.
366

367 **Figures**

368

369 Figure 1: A photograph of the CI positions as drawn onto a swim cap by an ENT surgeon experienced
370 in cochlear implantation. The CI was placed underneath each outline in turn for the acquisition of an
371 MR image in each participant. [Permission to use the image has been obtained from the subject.]

372

373 Figure 2: Extent of the CI artefact for each of the eight positions. Artefact extent was used to form a
374 binary mask. Coloured areas represent the number of participants (out of three) for whom that area
375 was obscured by image artefact generated by the CI. Bottom row shows the mathematical union of
376 all four positions on the left and right of the head, respectively. Images shown are in conventional
377 view (i.e. from below) and in MNI space. See supplemental material for raw images.

378

379 Figure 3: The relative artefact size, in terms of the percentage of the total head size in each of the
380 three participants and at each CI position. Positions 1 and 8 were the most anterior, positions 4 and
381 5 the most posterior. Red vertical bars represent the mean across three participants for each
382 position.

383

384 Figure 4: Radiological evaluation of artefact; impact of artefact on likely detection of abnormalities
385 for each of the 20 brain regions as shown by the modal rating across raters and participants. Higher
386 values, and red shading, indicate higher likelihood of an abnormality being missed by radiological
387 evaluation, whereas lower/blue indicates a comparatively low likelihood of missing pathology. It is
388 worth noting that there was a mode 9 brain regions out of 20 (range 7 to 14) that were deemed
389 unlikely to impact the identification of pathology across all CI locations.


390


391 **Tables**


392

393 Table 1: Absolute agreement between raters in terms of the number of disagreements with a
394 difference of more than 1 point on the scale, and Quadratic-Weighted Cohen's κ with 95%
395 confidence intervals. Percentage of disagreements based on a total number of 180 ratings (20 brain
396 regions across 8 CI locations and the control image).









	Subject 1	Subject 2	Subject 3
Total agreements	75 % (n = 135)	73 % (n = 132)	77 % (n = 139)
Disagreements > 1 point	7 % (n = 12)	9 % (n = 16)	7 % (n = 12)
Quadratic-Weighted Cohen's κ	0.70	0.72	0.78
κ 95% confidence interval	0.63 - 0.76	0.66 - 0.78	0.74 - 0.83

1

2 Table 1: Absolute agreement between raters in terms of the number of disagreements with a
3 difference of more than 1 point on the scale, and Quadratic-Weighted Cohen's κ with 95%
4 confidence intervals. Percentage of disagreements based on a total number of 180 ratings (20 brain
5 regions across 8 CI locations and the control image).



Click here to access/download
Supplemental Digital Content
Supplemental material.docx

